Drug survival of infliximab and adalimumab in inflammatory bowel disease

被引：0
|
作者：
Asadipour, Erfan [1 ]
Kargar, Mona [2 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Univ Tehran Med Sci, Res Ctr Rational Use Drugs, Tehran, Iran
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2020年 / 42卷 / 06期
关键词：
THERAPY;
D O I：
10.1007/s11096-020-01151-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1521 / 1523
页数：3
相关论文
共 50 条
  • [41] Infliximab in inflammatory bowel disease: 'Can we heal two disease with one drug?'
    Veerappan, Sundaram G.
    Healy, Martin
    Walsh, J. Bernard
    Kennedy, Mary
    O'Morain, Colm A.
    Ryan, Barbara M.
    Daly, Jacqueline
    GASTROENTEROLOGY, 2008, 134 (04) : A513 - A513
  • [42] Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease
    Holmstrom, Rikke B.
    Mogensen, Ditte V.
    Brynskov, Jorn
    Ainsworth, Mark A.
    Nersting, Jacob
    Schmiegelow, Kjeld
    Steenholdt, Casper
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (06) : 1583 - 1591
  • [43] Experience with therapeutic drug monitoring on adalimumab in paediatric inflammatory bowel disease (pIBD)
    Sider, S.
    Cococcioni, L.
    ElZein, A.
    Chadokufa, S.
    Buckingham, R.
    Shah, N.
    Ocholi, A.
    Borrelli, O.
    Kiparissi, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S566 - S566
  • [44] Adalimumab drug monitoring is superior to empirical treatment adjustment in inflammatory bowel disease
    Currais, P.
    Fernandes, S.
    Bernardo, S.
    Correia, L.
    Goncalves, A. R.
    Baldaia, C.
    Moura Santos, P.
    Valente, A.
    Tato Marinho, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S533 - S534
  • [45] Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease
    Rikke B. Holmstrøm
    Ditte V. Mogensen
    Jørn Brynskov
    Mark A. Ainsworth
    Jacob Nersting
    Kjeld Schmiegelow
    Casper Steenholdt
    Digestive Diseases and Sciences, 2018, 63 : 1583 - 1591
  • [46] A Comparison of Combination Therapy With Infliximab or Adalimumab and an Immunosuppressive Agent Versus Monotherapy in Patients With Inflammatory Bowel Disease
    Barnes, Edward L.
    Lucci, Matthew B.
    Collins, Emily
    Cao, Bonnie
    Carrellas, Madeline
    Crowell, Anne Marie
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2015, 148 (04) : S268 - S268
  • [47] Rapid desensitization for the management of hypersensitivity reaction to biologicals-Infliximab and adalimumab in inflammatory bowel disease patients
    Novotna, B.
    Prochazkova, L.
    Zboril, V
    Prokopova, L.
    Smerkova, H.
    ALLERGY, 2017, 72 : 223 - 224
  • [48] Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
    Tse, C. S.
    Loftus, E. V., Jr.
    Raffals, L. E.
    Gossard, A. A.
    Lightner, A. L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (02) : 190 - 195
  • [49] Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
    Raimundo Fernandes, S.
    Bernardo, S.
    Simoes, C.
    Correia, L.
    Moura Santos, P.
    Rita Goncalves, A.
    Valente, A.
    Baldaia, C.
    Tato Marinho, R.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S64 - S65
  • [50] REAL WORLD COMPARATIVE RISK OF SERIOUS INFECTION WITH ADALIMUMAB, VEDOLIZUMAB, AND INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Osterman, Mark T.
    Long, Millie D.
    Singh, Siddharth
    Meyer, Nicole
    Feng, Chaoling
    Higgins, Kate
    Hepp, Zsolt
    Arikan, Dilek
    Wang, Anthony
    Feagan, Brian G.
    GASTROENTEROLOGY, 2018, 154 (06) : S365 - S365
12345